Cefprozil-d4 |
| Catalog No.GC48593 |
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1426173-48-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Cefprozil-d4 is intended for use as an internal standard for the quantification of cefprozil by GC- or LC-MS. Cefprozil is an orally bioavailable, second generation, broad-spectrum cephalosporin antibiotic that inhibits the growth of both Gram-positive and Gram-negative bacteria.1,2 It inhibits the growth of E. coli, E. faecalis, E. faecium, N. gonorrhoeae, N. meningitidis, P. mirabilis, S. aureus, S. pyogenes, and S. pneumoniae strains (MICs = 0.013-25 μg/ml) and clinical isolates of penicillin-susceptible, -intermediate, and -resistant S. pneumoniae and methicillin-sensitive S. aureus (MIC90s = 0.12-16 μg/ml). In vivo, cefprozil protects mice challenged with E. coli, S. aureus, S. pyogenes, and P. mirabilis strains with protective doses (PD50s) ranging from 0.07 to 1.3 mg/kg.1 Cefprozil binds to penicillin-binding proteins (PBPs), which disrupts their ability to cross-link peptidoglycan and leads to weakened bacterial cell walls.3 Formulations containing cefprozil have been used in the treatment of respiratory tract, skin, and other bacterial infections.
1.Tomatsu, K., Ando, S., Masuyoshi, S., et al.In vitro and in vivo evaluations of BMY-28100, a new oral cephalosporinJ. Antibiot. (Tokyo)40(8)1175-1183(1987) 2.Peric, M., Browne, F.A., Jacobs, M.R., et al.Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: Use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agentsClin. Ther.25(1)169-177(2003) 3.Nagai, K., Davies, T.A., Jacobs, M.R., et al.Effects of amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b, and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and -resistant pneumococciAntimicrob. Agents Chemother.46(5)1273-1280(2002)
| Cas No. | 1426173-48-9 | SDF | |
| Canonical SMILES | O=C(O)C1=C(/C=C/C)CS[C@@]([C@@H]2NC([C@H](N)C3=C([2H])C([2H])=C(O)C([2H])=C3[2H])=O)([H])N1C2=O | ||
| Formula | C18H15D4N3O5S | M.Wt | 393.5 |
| Solubility | DMSO: soluble,Methanol: soluble,Water: soluble | Storage | -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5413 mL | 12.7065 mL | 25.413 mL |
| 5 mM | 0.5083 mL | 2.5413 mL | 5.0826 mL |
| 10 mM | 0.2541 mL | 1.2706 mL | 2.5413 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 1 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *